Company intelligence / Profile preview

AURELIUS

Basel, Basel-Stadt, Switzerland

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Aurealis Therapeutics has completed a Phase 1 trial of lead product AUP-16 in non‑healing diabetic foot ulcers and is running/has completed the DIAMEND Phase 2 randomized controlled trial, where blinded-evaluator results reported that AUP-16 tripled complete wound closure rates versus control in chronic diabetic foot ulcer patients.[5][7]

Therapeutic areas: ImmunologyEndocrinologyCardiovascularDermatologyOncology
Modalities: Cell therapyGene therapyBiologic
Industry: Biotech

Partnerships

Regional licensing agreement for AUP-16 in China with an unnamed partner (total deal value up to $139M plus royalties)[1]

Beyond the preview

Go deeper on AURELIUS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AURELIUS.

Explore the full profile